Catalent Stock Shows Improved Relative Strength Rating

On Friday, catalysts (CTLT) the stock earns a positive correction to it Relative Strength Rating (RS)from 63 to 74.


When searching best stocks to buy and watchOne factor to watch closely is relative price strength.

IBD’s proprietary ratings determine stock price movements with a score of 1 (worst) to 99 (best). The score shows a stock’s price behavior over the past 52 weeks relative to all other stocks in our database.

Decades of market research show that the best performing stocks often have an RS Rating above 80 in the early stages of a move. Let’s see if Catalent stock can continue to show new price strength and hit that benchmark.

See how IBD helps you make more money in stocks

Should Catalent Stock Buy?

Catalent stock does not present a suitable buying opportunity. See if the stock continues to build a chart pattern that could trigger a new bull run. Read “Looking for the next big stock market winners? Get started with these 3 steps” for more tips.

Earnings growth accelerated last quarter from -52% to -26%. But the revenue increase fell from 0% to -6%.

Catalent shares hold the 7th position among peers in the Medical Research Equipment/Services industry. PLC icon (ICLR) And Natera (NTRA) are also among the highest valued stocks.


MarketSmith’s tools can help individual investors

IBD Live: New tool for daily stock market analysis

Profit from short-term trends with SwingTrader

How to Research Growth Stocks: Why This IBD Tool Simplifies Finding Top Stocks


News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button